Alphatec Holdings, Inc. - Quarter Report: 2016 June (Form 10-Q)

Large accelerated filer

Accelerated filer

Non-accelerated filer

o (Do not check if a small reporting company)

Smaller reporting company

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-52024

ALPHATEC HOLDINGS, INC.

(Exact name of registrant as specified in its charter)



Delaware		20-2463898
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

5818 El Camino Real

Carlsbad, CA 92008

(Address of principal executive offices, including zip code)

(760) 431-9286

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No x As of August 8, 2016, there were 102,494,745 shares of the registrant’s common stock outstanding.

ALPHATEC HOLDINGS, INC.

QUARTERLY REPORT ON FORM 10-Q

June 30, 2016

Table of Contents



		Page
	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3

	Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015	3

	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2016 and 2015	4

	Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2016 and 2015	5

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and 2015	6

	Notes to Condensed Consolidated Financial Statements	8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36

Item 4.	Controls and Procedures	36

	PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	38

Item 1A.	Risk Factors	38

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41

Item 3.	Defaults Upon Senior Securities	42

Item 6.	Exhibits	42

SIGNATURES		43

PART I. FINANCIAL INFORMATION



Item 1.	Financial Statements

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except for par value data)



	June 30, 2016			December 31, 2015
Assets
Current assets:
Cash	$	9,322		$	11,229
Restricted cash	150			2,350
Accounts receivable, net	36,515			38,319
Inventories, net	44,141			44,908
Prepaid expenses and other current assets	3,559			4,689
Total current assets	93,687			101,495
Property and equipment, net	21,601			21,945
Intangible assets, net	19,756			21,616
Other assets	1,408			1,285
Total assets	$	136,452		$	146,341
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	17,447		$	14,169
Accrued expenses	30,459			29,791
Deferred revenue	799			648
Common stock warrant liabilities	1,145			687
Current portion of long-term debt	75,376			79,742
Total current liabilities	125,226			125,037
Long-term debt, less current portion	187			480
Other long-term liabilities	33,800			33,797
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at June 30, 2016 and December 31, 2015; 3,319 shares issued and outstanding at both June 30, 2016 and December 31, 2015	23,603			23,603
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.0001 par value; 200,000 authorized at June 30, 2016 and December 31, 2015; 102,495 and 102,158 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	10			10
Treasury stock, at cost, 19 shares, at both June 30, 2016 and December 31, 2015	(97		)	(97		)
Additional paid-in capital	417,360			416,939
Shareholder note receivable	(5,000		)	(5,000		)
Accumulated other comprehensive loss	(19,547		)	(21,188		)
Accumulated deficit	(439,090		)	(427,240		)
Total stockholders’ deficit	(46,364		)	(36,576		)
Total liabilities and stockholders’ deficit	$	136,452		$	146,341

See accompanying notes to unaudited condensed consolidated financial statements.

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(In thousands, except per share amounts)



	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Revenues	$	43,790		$	46,633		$	88,551		$	95,280
Cost of revenues	15,495			18,745			29,027			34,080
Amortization of acquired intangible assets	377			361			737			730
Gross profit	27,918			27,527			58,787			60,470
Operating expenses:
Research and development	2,080			3,912			5,747			7,763
Sales and marketing	18,138			16,644			37,260			34,839
General and administrative	8,270			9,241			18,917			18,379
Amortization of acquired intangible assets	491			669			977			1,346
Restructuring expenses	103			(112		)	789			(172		)
Total operating expenses	29,082			30,354			63,690			62,155
Operating loss	(1,164		)	(2,827		)	(4,903		)	(1,685		)
Other income (expense):
Interest income	16			12			36			19
Interest expense	(3,724		)	(3,040		)	(7,081		)	(6,411		)
Other income (expense), net	239			2,161			1,284			724
Total other income (expense)	(3,469		)	(867		)	(5,761		)	(5,668		)
Pretax net loss	(4,633		)	(3,694		)	(10,664		)	(7,353		)
Income tax provision	600			253			1,186			1,155
Net loss	$	(5,233	)	$	(3,947	)	$	(11,850	)	$	(8,508	)

Net loss per basic and diluted share	$	(0.05	)	$	(0.04	)	$	(0.12	)	$	(0.09	)

Shares used in calculating basic and diluted net loss per share	101,856			99,258			101,721			99,187

See accompanying notes to unaudited condensed consolidated financial statements.

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands)



	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Net loss	$	(5,233	)	$	(3,947	)	$	(11,850	)	$	(8,508	)
Foreign currency translation adjustments	849			1,539			1,641			(9,658		)
Comprehensive loss	$	(4,384	)	$	(2,408	)	$	(10,209	)	$	(18,166	)

See accompanying notes to unaudited condensed consolidated financial statements.

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)



	Six Months Ended June 30,
	2016			2015
Operating activities:
Net loss	$	(11,850	)	$	(8,508	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	7,381			9,587
Stock-based compensation	363			2,518
Interest expense related to amortization of debt discount and debt issuance costs	2,560			2,494
Provision for doubtful accounts	470			231
Provision for excess and obsolete inventory	2,374			1,574
Deferred income tax expense	(26		)	366
Other non-cash items	820			587
Changes in operating assets and liabilities:
Restricted cash	2,200			2,200
Accounts receivable	2,933			866
Inventories	(78		)	(1,316		)
Prepaid expenses and other current assets	1,292			1,075
Other assets	162			84
Accounts payable	3,077			1,657
Accrued expenses and other	(1,754		)	(9,783		)
Deferred revenues	148			(234		)
Net cash provided by operating activities	10,072			3,398
Investing activities:
Purchases of property and equipment	(5,691		)	(7,256		)
Cash received from sale of assets	1,316			—
Net cash used in investing activities	(4,375		)	(7,256		)
Financing activities:
Borrowings under lines of credit	70,155			73,463
Repayments under lines of credit	(70,963		)	(76,086		)
Principal payments on capital lease obligations	(400		)	(384		)
Proceeds from sale of stock	58			—
Principal payments on notes payable and term loan	(4,605		)	(4,351		)
Net cash used in financing activities	(5,755		)	(7,358		)
Effect of exchange rate changes on cash	(1,849		)	379
Net decrease in cash	(1,907		)	(10,837		)
Cash at beginning of period	11,229			19,735
Cash at end of period	$	9,322		$	8,898

See accompanying notes to unaudited condensed consolidated financial statements.

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)

(UNAUDITED)

(In thousands)



	Six Months Ended June 30,
	2016		2015
Supplemental disclosure of cash flow information:
Cash paid for interest	$	3,861	$	3,727
Cash paid for income taxes	$	896	$	362
Purchases of property and equipment in accounts payable	$	2,451	$	400

See accompanying notes to unaudited condensed consolidated financial statements.

ALPHATEC HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. The Company and Basis of Presentation

The Company

Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”), designs, develops, manufactures and markets products for the surgical treatment of spine disorders. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through the distribution channels of Alphatec Spine and its affiliate, Scient’x S.A.S., and its subsidiaries (“Scient’x”), via a direct sales force in Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America, the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Japan, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”).

Basis of Presentation

The accompanying condensed consolidated balance sheet as of December 31, 2015, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual audited financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made in this quarterly report on Form 10-Q are adequate to make the information not misleading. The interim unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the financial position and results of operations for the periods presented. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2015, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the SEC on March 15, 2016.

Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016, or any other future periods.

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through revenues from the sale of its products, equity financings and debt financings. As the Company has incurred losses, successful transition to profitability is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. This may not occur and, unless and until it does, the Company will continue to need to raise additional capital. Additionally, as discussed below, the Company has a significant amount of debt that is classified as current debt. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Operating losses and negative cash flows may continue for at least the next year as the Company continues to incur costs related to the execution of its operating plan and introduction of new products.

The Company's amended and restated credit facility (the "Amended Credit Facility") with MidCap Funding IV, LLC ("MidCap") matures in December 2016, which will require the Company to refinance the Amended Credit Facility with MidCap or to seek alternative financing. The Company has determined that it failed to comply with the fixed charge coverage ratio for January and June 2016, the fixed charge coverage ratio, senior leverage ratio and total leverage ratio covenants for March 2016, and the fixed charge coverage ratio and total leverage ratio covenants for April and May 2016, under its Amended Credit Facility with MidCap. The Company also did not meet a requirement for the percentage of the Company's total cash held in U.S. accounts for January, February, March, April, May and June 2016. The Company’s default under the MidCap credit facility also constitutes an event of default under the facility agreement (the "Facility Agreement") with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations International Master Fund, L.P., (collectively "Deerfield"). In March 2016, the Company received waivers from MidCap and Deerfield for the January non-compliance. In May 2016, MidCap and Deerfield provided waivers for the

February and March non-compliances, in June 2016, MidCap and Deerfield provided waivers for the April non-compliance and in August 2016, MidCap and Deerfield provided waivers for the May and June non-compliances. The Company can provide no assurance that it will be in compliance with the financial covenants for July 2016 or in the future. If the Company does not obtain waivers from MidCap or Deerfield for any existing or future non-compliances, they would have the right to call the debts due immediately, which would significantly impact the Company's ability to continue as a going concern. Management intends to pursue additional opportunities to raise additional capital through public or private equity offerings, debt financings, receivables financings or collaborations or partnerships with other companies to further support its planned operations. However, there is no assurance that it will be able to do so.

As disclosed in Note 14, subsequent to the balance sheet date the Company entered into a purchase and sale agreement with a third party (the "PSA") to divest substantially all of its international business operations in exchange for $80 million in cash, subject to a working capital adjustment and a loan of up to $30 million, subject to the satisfaction of the closing conditions set forth therein. The Company intends to use the proceeds from the sale to pay down a portion of its debt and improve its liquidity position and future cash flows. The transaction is expected to close in the second half of 2016.

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 to its audited consolidated financial statements for the year ended December 31, 2015, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 15, 2016. Except as discussed below, these accounting policies have not significantly changed during the six months ended June 30, 2016.

Fair Value Measurements

The carrying amount of financial instruments consisting of cash, restricted cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value.

Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:



Level 1:	Observable inputs such as quoted prices in active markets;
Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company does not maintain any financial instruments that are considered to be Level 1 or Level 2 instruments as of June 30, 2016 or December 31, 2015. The Company classifies its common stock warrant liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs. The following table provides a reconciliation of liabilities measured at fair value using significant unobservable inputs (Level 3) for the six months ended June 30, 2016 (in thousands):



	Common Stock Warrant Liabilities
Balance at December 31, 2015	$	687
Change in fair value	458
Balance at June 30, 2016	$	1,145

Common stock warrant liabilities are measured at fair value using the Black-Scholes option pricing valuation model. The assumptions used in the Black-Scholes option pricing valuation model for the common stock warrant liabilities were: (a) a risk-free interest rate based on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the remaining contractual term of the warrants; (b) an assumed dividend yield of zero based on the Company’s expectation that it will not pay dividends in the foreseeable future; (c) an expected term based on the remaining contractual term of the warrants; and (d) an expected volatility based upon the Company's historical volatility over the remaining contractual term of the warrants. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities associated with the

Deerfield Facility Agreement (described in Note 5 below) is the expected volatility. Significant increases in volatility would result in a higher fair value measurement.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance related to revenue recognition. This new standard replaces all current U.S. GAAP guidance on this topic and eliminates all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance, including all subsequent clarifications, is effective for the Company for annual and interim reporting periods in fiscal years beginning after December 15, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.

In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods thereafter. The Company is evaluating the impact of this guidance and expects to adopt the standard for the annual reporting period ending December 31, 2016.

In April 2015, the FASB issued guidance, which amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Prior to the issuance this guidance, debt issuance costs were required to be presented as an asset in the balance sheet. The Company adopted the provisions of the new guidance during the interim period ended March 31, 2016 and prior period amounts have been reclassified to conform to the current period presentation. As of December 31, 2015, $0.4 million of debt issuance costs were reclassified in the consolidated balance sheet from prepaid expenses and other current assets to current portion of long-term debt. The adoption of ASU 2015-03 did not impact the Company's consolidated statement of operations, comprehensive loss or cash flows.

In July 2015, the FASB issued new accounting guidance, which changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value for entities that do not measure inventory using the last-in, first-out or retail inventory method. The guidance also eliminates the requirement for these entities to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.

In February 2016, the FASB issued new accounting guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual periods and interim periods in fiscal years beginning after December 15, 2018. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.

In March 2016, the FASB issued new accounting guidance, which changes several aspects of the accounting for share-based payment award transactions, including accounting and cash flow classification for excess tax benefits and deficiencies, forfeitures, and tax withholding requirements and cash flow classification. The guidance is effective for annual periods and interim periods in fiscal years beginning after December 15, 2016. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.

3. Select Balance Sheet Details

Accounts Receivable, net

Accounts receivable, net consist of the following (in thousands):



	June 30, 2016			December 31, 2015
Accounts receivable	$	37,444		$	39,380
Allowance for doubtful accounts	(929		)	(1,061		)
Accounts receivable, net	$	36,515		$	38,319

Inventories, net

Inventories, net consist of the following (in thousands):



	June 30, 2016			December 31, 2015
Raw materials	$	6,938		$	7,237
Work-in-process	1,270			1,908
Finished goods	57,434			55,393
	65,642			64,538
Less reserve for excess and obsolete finished goods	(21,501		)	(19,630		)
Inventories, net	$	44,141		$	44,908

Property and Equipment, net

Property and equipment, net consist of the following (in thousands except as indicated):



	Useful lives (in years)	June 30, 2016			December 31, 2015
Surgical instruments	4	$	69,419		$	65,723
Machinery and equipment	7	10,380			15,520
Computer equipment	3	4,494			3,984
Office furniture and equipment	5	3,654			3,746
Leasehold improvements	various	3,906			3,856
Building	39	54			65
Land	n/a	11			9
Construction in progress	n/a	59			354
		91,977			93,257
Less accumulated depreciation and amortization		(70,376		)	(71,312		)
Property and equipment, net		$	21,601		$	21,945

Total depreciation expense was $2.5 million and $2.8 million for the three months ended June 30, 2016 and 2015, respectively. Total depreciation expense was $5.3 million and $5.6 million for the six months ended June 30, 2016 and 2015, respectively. At June 30, 2016, assets recorded under capital leases of $2.6 million were included in the machinery and equipment balance and $0.1 million were included in the construction in progress balance. At December 31, 2015, assets recorded under capital leases of $2.6 million were included in the machinery and equipment balance and $0.1 million were included in the construction in progress balance. Amortization of assets under capital leases was included in depreciation expense.

Intangible Assets, net

Intangible assets, net consist of the following (in thousands except for useful lives):



	Remaining Avg. Useful lives (in years)	June 30, 2016			December 31, 2015
Developed product technology	1	$	21,745		$	21,633
Distribution rights	4	2,393			2,100
Intellectual property	—	1,004			1,004
License agreements	1	16,717			16,714
Core technology	4	4,144			4,086
Trademarks and trade names	2	3,281			3,245
Customer-related	9	19,336			19,169
Distribution network	5	4,027			4,027
Physician education programs	—	2,549			2,513
Supply agreement	—	225			225
		75,421			74,716
Less accumulated amortization		(55,665		)	(53,100		)
Intangible assets, net		$	19,756		$	21,616

Total amortization expense was $1.0 million and $2.6 million for the three months ended June 30, 2016 and 2015, respectively. Total amortization expense was $2.1 million and $4.0 million for the six months ended June 30, 2016 and 2015, respectively.

Future amortization expense related to intangible assets as of June 30, 2016 is as follows (in thousands):



Year Ending December 31,
Remainder of 2016	$	2,029
2017	4,007
2018	2,867
2019	2,427
2020	1,823
Thereafter	6,603
	$	19,756

Accrued Expenses

Accrued expenses consist of the following (in thousands):



	June 30, 2016		December 31, 2015
Commissions and sales milestones	$	5,810	$	5,920
Payroll and payroll related	4,690		5,577
Litigation settlements	4,400		4,400
Accrued professional fees	2,207		2,203
Royalties	1,625		1,578
Restructuring and severance accruals	851		1,358
Accrued taxes	2,526		1,074
Accrued interest	970		999
Other	7,380		6,682
Total accrued expenses	$	30,459	$	29,791

4. License and Consulting Agreements

The Company’s license and consulting agreements are described in Note 4 to its audited consolidated financial statements for the year ended December 31, 2015, which are included in its Annual Report on Form 10-K which was filed with the SEC on March 15, 2016.

5. Debt

MidCap Facility Agreement

On August 30, 2013, the Company entered into the Amended Credit Facility with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had with MidCap (the "Prior Credit Facility"). Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity of the credit facility to August 2016. In July 2015, the Company further amended the Amended Credit Facility to provide for an additional term loan of $5 million. As of June 30, 2016, the Amended Credit Facility consisted of a $38 million term loan, $25 million of which was outstanding as of June 30, 2016 and a revolving line of credit with a maximum borrowing base of $40 million, of which $28 million was outstanding at June 30, 2016. The Company used the term loan proceeds of $28 million drawn at closing to repay a portion of the outstanding balance on the prior revolving line of credit.

The term loan interest rate is priced at the London Interbank Offered Rate ("LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate remains priced at LIBOR plus 6.0%, reset monthly. At June 30, 2016, the revolving line of credit carried an interest rate of 6.5% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries. In addition to monthly payments of interest, monthly repayments of $0.5 million are due through maturity, with the remaining principal due upon maturity.

The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by the Company. The Amended Credit Facility also includes several event of default provisions, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.

On March 17, 2014, the Company entered into a first amendment to the Amended Credit Facility with MidCap (the "First Amendment to the Amended Credit Facility"). Under the First Amendment to the Amended Credit Facility, MidCap gave the Company its consent to enter into the Facility Agreement (defined below) and make settlement payments in connection with the Orthotec litigation. The First Amendment to the Amended Credit Facility also added a total leverage ratio financial covenant.

On July 10, 2015, the Company entered into a Second Amendment to the Amended Credit Facility with MidCap (the "Second Amendment to the Amended Credit Facility") to increase the term loan commitment from $33 million to $38 million. The Company borrowed the additional $5 million under the term loan on July 10, 2015, which is the third term loan tranche under the Amended Credit Facility (the "Third Term Loan Tranche"). Until January 1, 2016, only interest payments were due for the Third Term Loan Tranche. Thereafter, the Company is required to pay an amount equal to $0.5 million on the first day of each calendar month as an amortization payment in respect of all tranches of the term loan. The Company paid MidCap, a commitment fee equal to 1.0% of the principal amount of the funds disbursed in the Third Term Loan Tranche.

In connection with the execution of the Amended Credit Facility, the Company incurred an additional $0.4 million in costs that were capitalized as debt issuance costs.

On March 11, 2016, the Company entered into a third amendment and waiver to the Amended Credit Facility with MidCap (the "Third Amendment to the Amended Credit Facility"). The Third Amendment to the Amended Credit Facility extended the maturity date of the Amended Credit Facility from August 30, 2016 to December 31, 2016 and contains an amendment fee in the amount of $0.5 million, which is due and payable at the earlier of the termination of the Amended Credit Facility or the maturity date. The Third Amendment to the Amended Credit Facility also contained a waiver of the December 2015 defaults under the Amended Credit Facility, provided a waiver for the fixed charge coverage ratio for January 2016 and eliminated the fixed charge coverage ratio covenant for February 2016. At June 30, 2016, $0.4 million remains as unamortized debt discount related to the prior and Amended Credit Facility within the unaudited consolidated balance sheet, which will be amortized over the remaining term of the Amended Credit Facility.

The Company was not in compliance with certain of the financial covenants of the Amended Credit Facility during the six months ended June 30, 2016, as disclosed in Note 1. There is no assurance that the Company will be in compliance with the financial covenants of the Amended Credit Facility in the future.

Deerfield Facility Agreement

On March 17, 2014, the Company entered into the Facility Agreement with Deerfield, pursuant to which Deerfield agreed to loan the Company up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, the Company had the option, but was not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015, provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described in Note 7 below. The Company agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed. Amounts borrowed under the Facility Agreement are payable on the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due on March 20, 2019.

In connection with the execution of the Facility Agreement on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock, which are immediately exercisable and have an exercise price equal to $1.39 per share (the “Initial Warrants”). Additionally, the Company agreed that each disbursement borrowing under the Facility Agreement be accompanied by the issuance to Deerfield of warrants to purchase up to 10,000,000 shares of the Company’s common stock, in proportion to the amount of draw compared to the total $50 million facility (the "Draw Warrants").

On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the settlement payment obligations that were due in 2014 to Orthotec, LLC. The $0.5 million transaction fee is recorded as a debt discount and is being amortized over the term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock at an exercise price of $1.39 per share, which were valued at $4.7 million and recorded as a debt discount, which is being amortized over the term of the $20 million draw. Additionally, $2.3 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method.

On November 21, 2014, the Company made a second draw of $6.0 million under the Facility Agreement and received net proceeds of $5.9 million to fund a portion of the Orthotec settlement payments due through 2016. The $0.2 million transaction fee was recorded as a debt discount and is being amortized over the remaining term of the draw, which ends March 20, 2019. In connection with this second draw, the Company issued Draw Warrants to purchase 1,200,000 shares of common stock at an exercise price of $1.39 per share, which were valued at $0.9 million and were recorded as a debt discount, which is being amortized over the term of the debt using the effective interest method. Additionally, $0.2 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method. No amounts remain available for the Company to borrow under the Facility Agreement.

On July 10, 2015, the Company entered into a First Amendment to the Facility Agreement (the “Facility Agreement First Amendment”), with Deerfield. The Facility Agreement First Amendment permitted, among other things, the Company to enter into and borrow the additional $5.0 million under the term loan in July 2015 under the Second Amendment to the Amended Credit Facility.

As of June 30, 2016, the outstanding Initial Warrants and Draw Warrants to purchase an aggregate of 11,450,000 shares of common stock were revalued to their fair value resulting in an expense of $0.6 million and $0.5 million for the three and six months ended June 30, 2016, respectively, included in other income/expense. The change in the fair value of the warrants of $0.5 million for the six months ended June 30, 2016 is included in other non-cash items in the condensed consolidated statements of cash flows. The warrant liability of $1.1 million is recorded as common stock warrant liabilities within current liabilities on the condensed consolidated balance sheet as of June 30, 2016.

At June 30, 2016, the outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:



	June 30, 2016
Risk-free interest rate	0.8	%
Dividend yield	—	%
Expected volatility	82	%
Expected life (years)	3.8

Prior to the expiration of the warrants, in connection with the PSA disclosed in Note 14, Deerfield has a right to convert its outstanding warrants into shares of the Company's common stock upon the closing of the transaction based on the Black-Scholes value of the warrant. If Deerfield does not convert such warrants prior to the end of the time period set forth in the warrants that it has to exercise such conversion, the warrants remain outstanding and exercisable with their terms.

On February 5, 2016, the Company entered into a Limited Waiver and Second Amendment to the Facility Agreement (the “Facility Agreement Second Amendment”) with Deerfield. The Facility Agreement Second Amendment increased the interest rate under the Facility Agreement from 8.75% per annum to 14.75% per annum. In addition, the Facility Agreement Second Amendment provides that the Company may elect to have (i) until August 30, 2016, six percent (6%), and (ii) thereafter, three percent (3%), in each case, of the interest on the outstanding principal amount under the Facility Agreement paid in kind, which would be added to the outstanding principal amount under the Facility Agreement and bear interest at the interest rate of 14.75% per annum (the “PIK Interest”). All accrued and unpaid PIK Interest is due and payable when the outstanding amounts under the Facility Agreement are due and payable thereunder or are fully repaid, whichever occurs first. The Facility Agreement Second Amendment also contains an amendment fee in the amount of $0.6 million, which is due and payable in installments of $0.2 million on each of the third, fourth and fifth anniversaries of the Facility Agreement; provided that all unpaid amendment fees shall be due and payable when the outstanding amounts under the Facility Agreement are due and payable or are fully repaid, whichever occurs first. The Facility Agreement Second Amendment also changes the date from March 31, 2017 to March 31, 2018, as the date through which the Company must pay interest in the event the Company prepays amounts outstanding under the Facility Agreement prior to such date. The Second Amendment also contains a waiver of the defaults under the Facility Agreement for the fixed charge coverage ratio for the month of January 2016.

The Facility Agreement contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. As security for the Company's repayment of its obligations under the Facility Agreement, the Company granted to Deerfield a security interest in substantially all of the Company's property and interests in property, which is subordinated to the security interest granted under the Amended Credit Facility.

As a result of the Company's non-compliance with the MidCap covenants, the Company was in cross-default of the Facility Agreement for which it received waivers from Deerfield. There is no assurance that the Company will be in compliance with the financial covenants of the Amended Credit Facility in the foreseeable future, which would result in a cross-default under the Facility Agreement in which case Deerfield would have the right to call the debt outstanding under the Facility Agreement due immediately. Accordingly, the amounts borrowed under the Facility Agreement are presented on the consolidated balance sheet as of June 30, 2016 under current liabilities, net of unamortized issuance discount.

Principal payments on debt are as follows as of June 30, 2016 (in thousands):




Year Ending December 31,
Remainder of 2016	$	53,360
2017 ⁽¹⁾	8,879
2018 ⁽¹⁾	8,879
2019 ⁽¹⁾	8,879
Total	79,997
Add: capital lease principal payments	878
Less: unamortized debt discount and debt issuance costs	(5,312		)
Total	75,563
Less: current portion of long-term debt ⁽¹⁾	(75,376		)
Long-term debt, net of current portion	$	187

⁽¹⁾ The amounts above are presented based on the contractual payment schedules in each of the respective agreements. However, the debt balance under the Facility Agreement is callable as of June 30, 2016 due to the events of default (See Note 1) and therefore, is presented as a current liability on the condensed consolidated balance sheet as of June 30, 2016.

6. Commitments and Contingencies

Leases

The Company leases certain equipment under capital leases which expire on various dates through 2017. The leases bear interest at rates ranging from 6.6% to 9.6% per annum, are generally due in monthly principal and interest installments and are collateralized by the related equipment. The Company also leases its buildings and certain equipment and vehicles under operating leases which expire on various dates through 2018. Future minimum annual lease payments under such leases are as follows as of June 30, 2016 (in thousands):



Year Ending December 31,	Operating		Capital
Remainder of 2016	$	1,817	$	429
2017	2,152		437
2018	1,688		68
2019	1,520		—
2020 and thereafter	2,396		—
	$	9,573	934
Less: amount representing interest			(56		)
Present value of minimum lease payments			878
Current portion of capital leases			(691		)
Capital leases, less current portion			$	187

Rent expense under operating leases for the three months ended June 30, 2016 and 2015 was $1.0 million and $0.7 million, respectively. Rent expense under operating leases for the six months ended June 30, 2016 and 2015 was $1.8 million and $1.5 million, respectively.

Litigation

The Company is and may become involved in various legal proceedings arising from its business activities. While management is not aware of any litigation matter that in and of itself would have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of a proceeding, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual or disclosure in the Company's consolidated financial statements. An estimated loss contingency is accrued in the Company’s consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated or unrelated to reasonably possible outcomes, and as such are not meaningful indicators of the Company’s potential liability.

Royalties

The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying condensed consolidated statement of operations as a component of cost of revenues.

7. Orthotec Settlement

On September 26, 2014, the Company entered into a Settlement and Release Agreement, dated as of August 13, 2014, by and among the Company and its direct subsidiaries, including Alphatec Spine, Inc., Alphatec Holdings International C.V., Scient'x S.A.S. and Surgiview S.A.S.; HealthpointCapital, LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., John H. Foster and Mortimer Berkowitz III; and Orthotec, LLC and Patrick Bertranou, (the "Settlement Agreement"). Pursuant to the Settlement Agreement, the Company agreed to pay Orthotec, LLC $49.0 million in cash, including initial cash payments totaling $1.75 million, which the Company previously paid in March 2014, and an additional lump sum payment of $15.75 million, which the Company previously paid in April 2014. The Company agreed to pay the remaining $31.5 million in 28 quarterly installments of $1.1 million and then one additional quarterly installment of $0.7 million, commencing October 1, 2014.

As of June 30, 2016, the Company has made installment payments in the aggregate of $25.2 million. The Company has the right to prepay the amounts due without penalty. In addition, the unpaid balance of the amounts due accrues interest at the rate of 7% per year beginning May 15, 2014 until the amounts due are paid in full. The accrued but unpaid interest will be paid in quarterly installments of $1.1 million (or the full amount of the accrued but unpaid interest if less than $1.1 million) following the full payment of the $31.5 million in quarterly installments described above. No interest will accrue on the accrued interest. The Settlement Agreement provided for mutual releases of all claims in the Orthotec, LLC v. Surgiview, S.A.S, et al. matter in the Superior Court of California, Los Angeles County and all other related litigation matters involving the Company and its directors and affiliates.

8. Net Loss Per Share

Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company, options, performance-based restricted stock units and warrants are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	(5,233	)	$	(3,947	)	$	(11,850	)	$	(8,508	)
Denominator:
Weighted average common shares outstanding	102,311			100,162			102,231			100,054
Weighted average unvested common shares subject to repurchase	(455		)	(904		)	(510		)	(867		)
Weighted average common shares outstanding—basic	101,856			99,258			101,721			99,187
Effect of dilutive securities:
Conversion of preferred stock	—			—			—			—
Options	—			—			—			—
Warrants	—			—			—			—
Weighted average common shares outstanding—diluted	101,856			99,258			101,721			99,187
Net loss per share:
Basic and diluted	$	(0.05	)	$	(0.04	)	$	(0.12	)	$	(0.09	)

The anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2016	2015	2016	2015
Options to purchase common stock	7,305	6,954	7,423	7,135
Unvested restricted share awards	455	904	510	867
Warrants to purchase common stock	11,544	11,544	11,544	11,544
Total	19,304	19,402	19,477	19,546

9. Stock Benefit Plans and Stock-Based Compensation

In February 2015 and July 2014, the Company granted 1,854,000 and 932,000 performance-based restricted stock units ("PSUs"), respectively, to certain employees under its 2005 Employee, Director and Consultant Stock Plan (the "2005 Plan"). The PSUs vest based upon the Company's achievement of certain performance goals over the period from January 2015 through December 2017 for the PSUs granted in 2015 and from July 2014 through December 2016 for the PSUs granted in 2014. The number of PSUs that may vest varies between 0%-200% based on the achievement of such goals. The PSUs were valued at $1.35 per share for the 2015 grants and $1.45 per share for the 2014 grants which was based on the closing price of the Company's common stock on the date of grant. For purposes of measuring compensation expense, the amount of PSUs ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The PSUs granted in 2015 are deemed not probable of vesting and the PSUs granted on 2014 were deemed not probable of vesting as of March 31, 2016, which resulted in an adjustment to reduce the stock-based compensation expense by $0.5 million during the first quarter of the six-month period ended June 30, 2016.

The 2005 Plan expired in May 2016 and has not been replaced with a new equity compensation plan as of June 30, 2016. The awards previously issued under the 2005 Plan remain outstanding.

10. Income Taxes

To calculate its interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or the tax environment changes.

The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company’s unrecognized tax benefits decreased by less than $0.1 million during the six months ended June 30, 2016. The decrease in unrecognized tax benefits during the six months ended June 30, 2016 was primarily related to foreign currency fluctuations, partially offset by increases related to federal and state research credits. The unrecognized tax benefits at June 30, 2016 and December 31, 2015 were $10.3 million and $10.4 million, respectively. With the facts and circumstances currently available to the Company, it is reasonably possible that the amount that could reverse over the next 12 months is approximately $0.2 million. Additionally, the French restructuring (see Note 12) may result in limitations on the Company’s ability to utilize its French net operating loss carryforwards to offset future taxable income.

The income tax provision consists primarily of income tax provisions related to state income taxes and operations in other foreign jurisdictions where the Company operates. The Company's effective tax rate of (9.1)% for the three months ended June 30, 2016 differs from the federal statutory rate of 35% primarily due to a full U.S. valuation allowance, state income taxes and foreign operations.

The Company is not currently under examination by the Internal Revenue Service, or by any foreign, state or local tax authorities.

11. Segment and Geographical Information

Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and one reportable business segment.

During the three and six months ended June 30, 2016 and 2015, the Company operated in two geographic regions, the U.S. and International, which consists of locations outside of the U.S. In the International geographic region, sales in Japan for the three and six months ended June 30, 2016 totaled $8.2 million and $17.4 million, respectively, which represented greater than 10 percent of the Company’s consolidated revenues for such periods. In the International geographic region, sales in Japan for the three and six months ended June 30, 2015 totaled $7.9 million and $15.4 million, respectively, which represented greater than 10 percent of the Company’s consolidated revenues for such periods.

Revenues attributed to the geographic location of the customer were as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
United States	$	28,171	$	27,247	$	57,257	$	57,714
International	15,619		19,386		31,294		37,566
Total consolidated revenues	$	43,790	$	46,633	$	88,551	$	95,280

Total assets by region were as follows (in thousands):



	June 30, 2016		December 31, 2015
United States	$	84,620	$	97,604
International	51,832		48,737
Total consolidated assets	$	136,452	$	146,341

12. Restructuring

In 2015, the Company initiated plans to close its operations in France. The Company recorded total costs of less than $0.1 million and $0.6 million during the three and six months ended June 30, 2016, respectively, related to employee severance and related taxes in regards to this closure.

On July 6, 2015, the Company announced a restructuring of its manufacturing operations in California in an effort to improve its cost structure. The restructuring includes a reduction in workforce and closing the California manufacturing facility. The Company incurred expenses of $0.1 million and $0.2 million during the three and six months ended June 30, 2016, respectively, related to these restructuring activities.

As of June 30, 2016, the restructuring activities in France and California were substantially complete.

13. Related Party Transactions

For the six months ended June 30, 2016 and 2015, respectively, the Company incurred expenses of less than $0.1 million related to HealthpointCapital, LLC. As of June 30, 2016, the Company also had a liability of less than $0.1 million payable to HealthpointCapital, LLC for travel and administrative expenses.

Subsequent to the balance sheet date, the Company entered into a forbearance agreement with HealthpointCapital, LLC, HealthpointCapital Partners, L.P., and HealthpointCapital Partners II, L.P. (collectively, "HealthpointCapital"), pursuant to which HealthpointCapital, on behalf of the Company, paid $1.0 million of the $1.1 million payment due and payable by the Company to Orthotec on July 1, 2016 and agreed to not exercise its ability to seek an immediate repayment of such amount. Pursuant to this agreement, the Company is required to repay this amount, without interest, to HealthpointCapital by September 30, 2016.

14. Subsequent Events

On July 25, 2016, the Company entered into the PSA with Globus Medical Ireland, Ltd. (the “Buyer”), a subsidiary of Globus Medical, Inc. (“Globus”), pursuant to which, and on the terms and subject to the conditions thereof, among other things, the Buyer agreed to acquire all of the Company’s international distribution operations and agreements, including the Company’s wholly-owned subsidiaries in Japan and Brazil and substantially all of the assets of the Company’s other sales operations in the United Kingdom and Italy.

Under the terms of the PSA, at the closing (the “Closing”) of the transaction the Buyer will pay the Company $80 million in cash, subject to a working capital adjustment (the “Closing Payment”). At the Closing, the Company will use approximately $69 million of the Closing Payment to (i) repay in full all amounts outstanding and due under the Company’s Deerfield Facility Agreement and (ii) repay certain of its outstanding indebtedness under the Company’s MidCap Amended Credit Facility, in each case, including debt-related costs. At the Closing, the Company will enter into a five-year term credit facility agreement (the “Globus Facility Agreement”) with Globus, pursuant to which Globus will agree to loan the Company up to $30 million, subject to the terms and conditions set forth in the Globus Facility Agreement

The transaction is expected to close in the second half of 2016 and is subject to the satisfaction of the closing conditions set forth in the PSA. As of June 30, 2016, the criteria for reporting the transaction as discontinued operations were not met.

On August 8, 2016, the Company entered into a fourth amendment to the Amended Credit Facility with MidCap (the "Fourth Amendment to the Amended Credit Facility"). The Fourth Amendment provides for a $2.2 million increase to the borrowing base until September 15, 2016, and includes an amendment fee of $0.2 million, which was due and payable on August 8, 2016. The Fourth Amendment to the Amended Credit Facility also contains a waiver for the May and June 2016 non-compliances.



Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following management's discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 15, 2016. In addition to historical information the following management’s discussion and analysis of our financial condition and results of operations includes forward-looking information that involves risks, uncertainties, and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, such as those set forth in our Annual Report on Form 10-K for the year ended December 31, 2015 and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC.

Overview

We are a medical technology company focused on the design, development and promotion of products for the surgical treatment of spine disorders. We have a comprehensive product portfolio and pipeline that addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a variety of spinal disorders and surgical procedures. Our principal product offerings are focused on the global market for fusion-based spinal disorder solutions. We believe that our products and systems are attractive to surgeons and patients due to enhanced product features and benefits that are designed to simplify surgical procedures and improve patient outcomes.

Recent Developments

On July 25, 2016, we entered into a purchase and sale agreement, or the Purchase and Sale Agreement, with Globus Medical Ireland, Ltd., or the Buyer, a subsidiary of Globus Medical, Inc., or Globus, pursuant to which, and on the terms and subject to the conditions thereof, among other things, the Buyer agreed to acquire all of our international distribution operations and agreements, including our wholly-owned subsidiaries in Japan and Brazil and substantially all of the assets of our other sales operations in the United Kingdom and Italy.

Under the terms of the Purchase and Sale Agreement, at the closing, or the Closing, of the transaction the Buyer will pay us $80 million in cash, subject to a working capital adjustment, or the Closing Payment. At the Closing, we will use approximately $69 million of the Closing Payment to (i) repay in full all amounts outstanding and due under our Deerfield Facility Agreement and (ii) repay certain of our outstanding indebtedness under our MidCap Amended Credit Facility, in each case, including debt-related costs. At the Closing, we will enter into a five-year term credit facility agreement, or the Globus Facility Agreement, with Globus, pursuant to which Globus will agree to loan us up to $30 million, subject to the terms and conditions set forth in the Globus Facility Agreement.

The transaction is expected to close by October 2016 and is subject to the satisfaction of the closing conditions set forth in the Purchase and Sale Agreement.

Revenue and Expense Components

The following is a description of the primary components of our revenues and expenses:

Revenues. We derive our revenues primarily from the sale of spinal surgery implants used in the treatment of spine disorders. Spinal implant products include pedicle screws and complementary implants, interbody devices, plates, and tissue-based materials. Our revenues are generated by our direct sales force and independent distributors. Our products are requested directly by surgeons and shipped and billed to hospitals and surgical centers. We have existing subsidiaries and/or affiliates in Japan, Germany, Brazil, Italy and the U.K. through which we sell our products and independent distributors in over 50 countries throughout the world. A majority of our business is conducted with customers within markets in which we have experience and with payment terms that are customary to our business. We may defer revenues until the time of collection if circumstances related to payment terms, regional market risk or customer history indicate that collectability is not reasonably assured.

Cost of revenues. Cost of revenues consists of direct product costs, royalties, milestones, depreciation of our surgical instruments, and the amortization of purchased intangibles. Our product costs consist primarily of direct labor, manufacturing overhead, and raw materials and components. The product costs of certain of our biologics products include the cost of procuring and processing human tissue. We incur royalties related to the technologies that we license from others and the products that are developed in part by surgeons with whom we collaborate in the product development process. Amortization of purchased intangibles consists of amortization of developed product technology.

Research and development expense. Research and development expense consists of costs associated with the design, development, testing, and enhancement of our products. Research and development expense also includes salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers in both cash and equity, and costs associated with our Scientific Advisory Board and Executive Surgeon Panels.

Sales and marketing expense. Sales and marketing expense consists primarily of salaries and related employee benefits, sales commissions and support costs, professional service fees, travel, medical education, trade show and marketing costs.

General and administrative expense. General and administrative expense consists primarily of salaries and related employee benefits, professional service fees and legal expenses.

Restructuring expense. Restructuring expense consists of severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs and contract termination costs incurred in connection with the reorganization of the Scient’x operations in France and the termination of our manufacturing operations in California.

Total other income (expense). Total other income (expense) includes interest income, interest expense, changes in the fair value of the warrant liabilities, gains and losses from foreign currency exchanges, and other non-operating gains and losses.

Income tax provision. Income tax provision consists primarily of income tax provision related to state income taxes and operations in foreign jurisdictions where the Company operates.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an on-going basis, we evaluate our estimates and assumptions, including those related to revenue recognition, allowances for accounts receivable, inventories, goodwill and intangible assets, stock-based compensation and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumption conditions.

Critical accounting policies are those that, in management’s view, are most important in the portrayal of our financial condition and results of operations. Except for the changes disclosed in Note 2 to the Notes to Condensed Consolidated Financial Statements included in Item 1, Part I of this Quarterly Report on Form 10-Q, management believes there have been no material changes during the six months ended June 30, 2016 to the critical accounting policies discussed in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 15, 2016.

Results of Operations

The table below sets forth certain statements of operations data for the periods indicated (in thousands). Our historical results are not necessarily indicative of the operating results that may be expected in the future.



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Revenues	$	43,790		$	46,633		$	88,551		$	95,280
Cost of revenues	15,495			18,745			29,027			34,080
Amortization of acquired intangible assets	377			361			737			730
Gross profit	27,918			27,527			58,787			60,470
Operating expenses:
Research and development	2,080			3,912			5,747			7,763
Sales and marketing	18,138			16,644			37,260			34,839
General and administrative	8,270			9,241			18,917			18,379
Amortization of acquired intangible assets	491			669			977			1,346
Restructuring expense	103			(112		)	789			(172		)
Total operating expenses	29,082			30,354			63,690			62,155
Operating loss	(1,164		)	(2,827		)	(4,903		)	(1,685		)
Other income (expense):
Interest income	16			12			36			19
Interest expense	(3,724		)	(3,040		)	(7,081		)	(6,411		)
Other income (expense), net	239			2,161			1,284			724
Total other income (expense)	(3,469		)	(867		)	(5,761		)	(5,668		)
Pretax net loss	(4,633		)	(3,694		)	(10,664		)	(7,353		)
Income tax provision	600			253			1,186			1,155
Net loss	$	(5,233	)	$	(3,947	)	$	(11,850	)	$	(8,508	)

Three Months Ended June 30, 2016 Compared to the Three Months Ended June 30, 2015

Revenues. Revenues were $43.8 million for the three months ended June 30, 2016 compared to $46.6 million for the three months ended June 30, 2015, representing a decrease of $2.8 million, or 6.1%. The decrease was the result of a decline in the International region ($3.8 million) offset by an increase in the U.S. region ($0.9 million).

U.S. revenues were $28.2 million for the three months ended June 30, 2016 compared to $27.2 million for the three months ended June 30, 2015, representing an increase of $0.9 million, or 3.4%. The increase was due to growth in sales directly to hospitals ($2.4 million), offset by a reduction in sales to stocking distributors ($1.5 million).

International revenues were $15.6 million for the three months ended June 30, 2016 compared to $19.4 million for the three months ended June 30, 2015, representing a decrease of $3.8 million, or 19.4%. The decrease was the result of a decline in implant and instrument sales ($4.6 million), offset by the favorable exchange rate effect ($0.8 million).

Cost of revenues. Cost of revenues was $15.5 million for the three months ended June 30, 2016 compared to $18.7 million for the three months ended June 30, 2015, representing a decrease of $3.3 million, or 17.3%. The decrease was the result of a reduction in product costs due to volume and mix ($1.4 million), gains recognized on the disposal of various manufacturing equipment ($0.8 million), the absence of one-time expenses incurred in 2015 related to product discontinuations and equipment disposals ($1.9 million), a reduction in royalty expense ($0.1 million) and a reduction in amortization expense ($0.2 million), offset by an increase in reserves and adjustments ($1.1 million).

Amortization of acquired intangible assets. Amortization of acquired intangible assets was $0.4 million for the three months ended June 30, 2016 and for the three months ended June 30, 2015. This expense represented amortization in the period for intangible assets associated with product related assets obtained in acquisitions.

Gross profit. Gross profit was $27.9 million for the three months ended June 30, 2016 compared to $27.5 million for the three months ended June 30, 2015, representing an increase of $0.4 million, or 1.4%. The increase was due to a reduction in

cost of revenues ($3.3 million) and favorable exchange rate effect ($0.8 million), offset by a decline in sales volume ($3.7 million).

Gross margin. Gross margin was 63.8% for the three months ended June 30, 2016 compared to 59.0% for the three months ended June 30, 2015. The increase of 4.8 percentage points was due to a favorable variation in regional mix and product mix (1.5 percentage points), gains recognized on the disposal of various manufacturing equipment (1.8 percentage points), the absence of one-time expenses incurred in 2015 related to product discontinuations and equipment disposals (4.1 percentage points) and a reduction in amortization (0.2 percentage points), offset by an increase in reserves and adjustments (2.4 percentage points) and an increase in instrument depreciation (0.4 percentage points).

Gross margin for the U.S. region was 67.4% for the three months ended June 30, 2016 compared to 60.3% for the three months ended June 30, 2015. The increase of 7.1 percentage points was due to gains recognized on the sale of various manufacturing equipment (2.8 percentage points), the absence of one-time expenses incurred in 2015 related to product discontinuations and equipment disposals (7.0 percentage points), a reduction in amortization expenses (0.6 percentage points), a decrease in instrument depreciation (0.3 percentage points), a decrease in royalties due to a change in product mix (0.5 percentage points) and favorable variation in pricing and product mix (0.3 percentage points), offset by an increase in inventory reserves and adjustments (4.4 percentage points).

Gross margin for the International region was 57.2% for the three months ended June 30, 2016 compared to 57.3% for the three months ended June 30, 2015. The decrease of 0.1 percentage points was the result of an increase in royalties (0.6 percentage points), an increase in depreciation (1.0 percentage points) and an increase in amortization (0.6 percentage points), offset by favorable variation in regional mix and product mix (0.8 percentage points) and a decrease in inventory reserves and adjustments (1.3 percentage points).

Research and development expense. Research and development expense was $2.1 million for the three months ended June 30, 2016 compared to $3.9 million for the three months ended June 30, 2015, representing a decrease of $1.8 million, or 46.8%. The decrease was related to a decrease in personnel costs ($0.6 million) and a reduction of development activities ($1.2 million).

Sales and marketing expense. Sales and marketing expense was $18.1 million for the three months ended June 30, 2016 compared to $16.6 million for the three months ended June 30, 2015, representing an increase of $1.5 million, or 9.0%. The increase was the result of greater commission expense ($2.5 million), offset by the elimination of the medical device excise tax ($0.3 million) and a reduction in general sales and marketing expenses ($0.7 million).

General and administrative expense. General and administrative expense was $8.3 million for the three months ended June 30, 2016 compared to $9.2 million for the three months ended June 30, 2015, representing a decrease of $1.0 million, or 10.5%. The decrease was due to a reduction in personnel costs ($0.7 million) and a decrease in legal, accounting and other professional services expenses ($1.5 million), offset by non-recurring transaction expenses related to the proposed sales of the International business ($1.2 million).

Amortization of acquired intangible assets. Amortization of acquired intangible assets was $0.5 million for the three months ended June 30, 2016 compared to $0.7 million for the three months ended June 30, 2015. This expense represents amortization in the period for intangible assets associated with general business assets obtained in acquisitions and has decreased as a result of impairment of these assets in 2015.

Restructuring expense. Restructuring expense was $0.1 million for the three months ended June 30, 2016 compared to a credit of $0.1 million for the three months ended June 30, 2015. In July 2015, we announced a restructuring of our manufacturing operations in California in an effort to improve our cost structure. As of June 30, 2016, the manufacturing restructuring was substantially complete and we recorded expenses of approximately $0.1 million in the three months ended June 30, 2016. On September 16, 2013, we announced that Scient'x had begun a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. As of June 30, 2016 substantially all the activities associated with the restructuring were completed and substantially all of the costs associated with the restructuring have been expensed.

Interest expense, net. Interest expense, net, was $3.7 million for the three months ended June 30, 2016 and $3.0 million for the three months ended June 30, 2015 representing an increase of $0.7 million, or 22.5%. This increase is primarily related to greater costs in connection with various amendments to our credit facilities with MidCap and Deerfield.

Other income (expense), net. Other income (expense), net was net income of $0.2 million for the three months ended June 30, 2016 compared to net income of $2.2 million for the three months ended June 30, 2015, representing a decrease in income of $1.9 million. The decrease in income was the result of an increase in expense related to warrant valuation ($2.4 million), offset by a net favorable foreign currency exchange results ($0.2 million).

Income tax provision. Income tax provision was $0.6 million for the three months ended June 30, 2016 compared to $0.3 million for the three months ended June 30, 2015. The 2016 income tax expense provision consists of state and foreign income taxes. The 2015 income tax expense provision consists primarily of state and foreign income taxes and the tax effect of changes in deferred tax liabilities associated with tax deductible goodwill.

Six Months Ended June 30, 2016 Compared to the Six Months Ended June 30, 2015

Revenues. Revenues were $88.6 million for the six months ended June 30, 2016 compared to $95.3 million for the six months ended June 30, 2015, representing a decrease of $6.7 million, or 7.1%. The decrease was the result of a decrease in the U.S. region ($0.5 million) combined with a decrease in the International region ($6.3 million).

U.S. revenues were $57.3 million for the six months ended June 30, 2016 compared to $57.7 million for the six months ended June 30, 2015, representing a decrease of $0.5 million, or 0.8%. The decrease was the result of lower sales directly to stocking distributors ($3.1 million), offset by an increase in direct sales to hospitals ($2.6 million).

International revenues were $31.3 million for the six months ended June 30, 2016 compared to $37.6 million for the six months ended June 30, 2015, representing a decrease of $6.3 million, or 16.7%. The decrease was the result of a decline in implants and instruments sales ($7.1 million), offset by favorable exchange rate effect ($0.8 million).

Cost of revenues. Cost of revenues was $29.0 million for the six months ended June 30, 2016 compared to $34.1 million for the six months ended June 30, 2015, representing a decrease of $5.1 million, or 14.8%. The decrease was the result of a decrease in product costs due to volume and mix ($3.3 million), gains recognized on the sale of various manufacturing equipment ($1.3 million), the absence of one-time expenses incurred in 2015 related to product discontinuation and equipment disposals ($1.9 million), a reduction in royalty expense ($0.2 million) and a reduction in amortization expense ($0.3 million), offset by an increase in reserves and adjustments ($1.4 million), an increase in manufacturing depreciation expense due to the reduction in useful lives related to the manufacturing restructuring and closure of our California manufacturing operations ($0.3 million), and an increase in depreciation expense ($0.2 million).

Amortization of acquired intangible assets. Amortization of acquired intangible assets was $0.7 million for the six months ended June 30, 2016 compared to $0.7 million for the six months ended June 30, 2015. This expense represents amortization in the period for intangible assets associated with product related assets obtained in acquisitions.

Gross profit. Gross profit was $58.8 million for the six months ended June 30, 2016 compared to $60.5 million for the six months ended June 30, 2015, representing a decrease of $1.7 million, or 2.8%. The decrease was due to a decline in sales volume ($6.8 million), offset by a reduction in cost of revenues ($5.1 million).

Gross margin. Gross margin was 66.4% for the six months ended June 30, 2016 compared to 63.5% for the six months ended June 30, 2015. The increase of 2.9 percentage points was due to favorable variation in regional mix and product mix (1.9 percentage points), gains recognized on the disposal of various manufacturing equipment, offset by increased equipment depreciation (1.1 percentage points), the absence of one-time expenses incurred in 2015 related to product discontinuation and equipment disposals (2.0 percentage points) and a reduction in amortization (0.3 percentage points), offset by an increase in reserves and adjustments (1.9 percentage points) and an increase in instrument depreciation (0.5 percentage points).

Gross margin for the U.S. region was 71.7% for the six months ended June 30, 2016 compared to 66.5% for the six months ended June 30, 2015. The increase of 5.2 percentage points was due to favorable variation in pricing and product mix (2.1 percentage points), gains recognized on the sale of various manufacturing equipment, offset by increased equipment depreciation (1.8 percentage points), the absence of one-time expenses incurred in 2015 related to product discontinuation and equipment disposals (3.3 percentage points), a reduction in amortization (0.5 percentage points) and a reduction in royalties (0.4 percentage points), offset by an increase in reserves and adjustments (2.9 percentage points).

Gross margin for the International region was 56.7% for the six months ended June 30, 2016 compared to 58.7% for the six months ended June 30, 2015. The decrease of 2.0 percentage points was due to unfavorable variation in pricing and product mix (0.4 percentage points), depreciation (1.1 percentage points), royalties (0.7 percentage points), amortization (0.4 percentage points), offset by a decrease in inventory reserves and adjustments (0.6 percentage points).

Research and development expense. Research and development expense was $5.7 million for the six months ended June 30, 2016 compared to $7.8 million for the six months ended June 30, 2015, representing a decrease of $2.0 million, or 26.0%. The decrease was related to a decrease in personnel costs ($0.9 million) and a reduction of development activities ($1.1 million).

Sales and marketing expense. Sales and marketing expense was $37.3 million for the six months ended June 30, 2016 compared to $34.8 million for the six months ended June 30, 2015, representing an increase of $2.4 million, or 6.9%. The increase was the result of greater commission expense ($3.7 million), offset by the elimination of the medical device excise tax ($0.6 million) and a reduction in general sales and marketing expenses ($0.7 million).

General and administrative expense. General and administrative expense was $18.9 million for the six months ended June 30, 2016 compared to $18.4 million for the six months ended June 30, 2015, representing an increase of $0.5 million, or 2.9%. The increase was primarily due to non-recurring transaction expenses related to the proposed sale of the International business ($2.0 million), offset by a reduction in personnel costs ($0.7 million) and a decrease of legal, accounting and other professional services expenses ($0.8 million).

Amortization of acquired intangible assets. Amortization of acquired intangible assets was $1.0 million for the six months ended June 30, 2016 compared to $1.3 million for the six months ended June 30, 2015. This expense represents amortization in the period for intangible assets associated with general business assets obtained in acquisitions and has decreased as a result of impairment of these assets in 2015.

Restructuring expense. Restructuring expense was $0.8 million for the six months ended June 30, 2016 compared to a credit of $0.2 million for the six months ended June 30, 2015. In July 2015, we announced a restructuring of our manufacturing operations in California in an effort to improve our cost structure. As of June 30, 2016, the manufacturing restructuring is substantially complete and we recorded expenses of approximately $0.2 million in the six months ended June 30, 2016. On September 16, 2013, we announced that Scient'x had begun a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. As of June 30, 2016 substantially all the activities associated with the restructuring are completed and we recorded expenses of approximately $0.6 million in the six months ended June 30, 2016.

Interest expense, net. Interest expense, net was $7.0 million for the six months ended June 30, 2016 and $6.4 million for the six months ended June 30, 2015 representing an increase of $0.7 million, or 10.2%. This increase is primarily related to greater costs in connection with various amendments to our credit facilities with MidCap and Deerfield.

Other income (expense), net. Other income (expense), net was income of $1.3 million for the six months ended June 30, 2016 compared to income of $0.7 million for the six months ended June 30, 2015, representing an increase of $0.6 million. The increase in income is due to a favorable foreign currency exchange results ($2.6 million), offset by an increase in expense related to warrant valuation ($2.2 million).

Income tax provision. Income tax provision was $1.2 million for the six months ended June 30, 2016 compared to $1.2 million for the six months ended June 30, 2015. The 2016 income tax expense provision consists of state and foreign income taxes. The 2015 income tax expense provision consists primarily of state and foreign income taxes and the tax effect of changes in deferred tax liabilities associated with tax deductible goodwill.

Non-GAAP Financial Measures

We utilize certain financial measures that are not calculated based on U.S. generally accepted accounting principles, or GAAP. Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures reflect an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are unaudited and are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors.

Adjusted EBITDA represents net income (loss) excluding the effects of interest, taxes, depreciation, amortization, stock-based compensation, other income (expense) and other non-recurring income or expense items, such as asset impairments, litigation expenses and restructuring and other expenses. We believe that the most directly comparable GAAP financial measure to adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations. Therefore, adjusted EBITDA should not be considered either in isolation or as a substitute for analysis of our results as reported under GAAP. Furthermore, adjusted EBITDA should not be considered as an alternative to operating income (loss) or net income (loss) as a measure of operating performance or to net cash provided by operating, investing or financing activities, or as a measure of our ability to meet our cash needs.

The following is a reconciliation of adjusted EBITDA to the most comparable GAAP measure, net loss, for the three and six months ended June 30, 2016 and 2015 (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Net loss	$	(5,233	)	$	(3,947	)	$	(11,850	)	$	(8,508	)
Stock-based compensation	306			1,265			363			2,518
Depreciation	2,464			2,836			5,337			5,627
Amortization of intangible assets	165			1,559			330			1,884
Amortization of acquired intangible assets	867			1,030			1,714			2,076
Stock price guarantee	354			—			1,160			—
Interest expense, net	3,708			3,028			7,045			6,392
Income tax provision	600			253			1,186			1,155
Other (income) expense, net	(239		)	(2,161		)	(1,284		)	(724		)
Restructuring and other expense	2,096			(112		)	2,782			(172		)
Adjusted EBITDA	$	5,088		$	3,751		$	6,783		$	10,248

Liquidity and Capital Resources

We have incurred significant net losses since inception and relied on our ability to fund our operations through revenues from the sale of our products, equity financings and debt financings. As we have incurred losses, a successful transition to profitability is dependent upon achieving a level of revenues adequate to support our cost structure. This may not occur and, unless and until it does, we will continue to need to raise additional capital. At June 30, 2016, our principal sources of liquidity consisted of unrestricted cash of $9.3 million and accounts receivable, net of $36.5 million. Additionally, as discussed below, we have a significant amount of debt that is classified as current debt. Operating losses and negative cash flows may continue for at least the next year as we continue to incur costs related to the execution of our operating plan, introduction of new products and expansion into new geographies.

Our amended and restated credit facility with MidCap Funding IV, LLC, or MidCap, as amended, or the Amended Credit Facility, matures in December 2016, which will require us to refinance the Amended Credit Facility with MidCap or seek alternative financing. Without modifications to our existing payment obligations or receipt of funding through our purchase and sale agreement discussed below or otherwise, our existing cash and other sources of liquidity may only be sufficient to fund our operations until our Amended Credit Facility with MidCap matures in December 2016, assuming that our creditors continue to waive any breaches under our credit facilities and our debt is not accelerated. These circumstances raise substantial doubt about our ability to continue as a going concern. We may seek additional funds from public and private equity or debt financings, borrowings under new debt facilities or other sources to fund our projected operating requirements. However, there is no guarantee that we will be able to obtain further financing, or do so on reasonable terms. If we are unable to raise additional funds on a timely basis, or at all, we would be materially adversely affected.

We were not in compliance with the fixed charge coverage ratio for January and June 2016, the fixed charge coverage ratio, senior leverage ratio and total leverage ratio covenants for March 2016, and the fixed charge coverage ratio and total leverage ratio covenants for April and May 2016, under our Amended Credit Facility with MidCap. We also did not meet a minimum requirement for the percentage of our total cash held in U.S. accounts for January, February, March, April, May and June 2016. We obtained waivers from MidCap to cure the non-compliance for these covenants for such periods. Our default under the Amended Credit Facility with MidCap also constitutes an event of default under our facility agreement, or Facility Agreement, with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations International Master Fund, L.P., or collectively Deerfield, and such default has been similarly waived by Deerfield with respect to these covenants for these periods.

There is no assurance that we will be in compliance with the financial covenants of the Amended Credit Facility or the Facility Agreement in July 2016 or in the future. If we have future defaults and we do not obtain waivers from MidCap or Deerfield they would each have the right to call their respective debts due immediately, which would significantly impact our ability to continue as a going concern. We intend to pursue additional opportunities to raise additional capital through public or private equity offerings, debt financings, receivables financings or collaborations or partnerships with other companies to further support our planned operations. However, there is no assurance that we will be able to do so. Accordingly, as of June 30, 2016, there is substantial doubt about our ability to continue as a going concern through December 31, 2016.

Under the terms of the Purchase and Sale Agreement, at the closing, or the Closing, of the transaction the Buyer will pay us $80 million in cash, subject to a working capital adjustment, or the Closing Payment. At the Closing, we will use approximately $69 million of the Closing Payment to (i) repay in full all amounts outstanding and due under our credit facility with Deerfield and (ii) repay certain of our outstanding indebtedness under our credit facility with MidCap, in each case, including debt-related costs. At the Closing, we will enter into a five-year term credit facility agreement, or the Globus Facility Agreement, with Globus, pursuant to which Globus will agree to loan us up to $30 million, subject to the terms and conditions set forth in the Globus Facility Agreement.

The transaction is expected to close in the second half of 2016 and is subject to the satisfaction of the closing conditions set forth in the Purchase and Sale Agreement.

Historically, our principal sources of cash have included customer payments from the sale of our products, proceeds from the issuance of common and preferred stock and proceeds from the issuance of debt. Our principal uses of cash have included cash used in operations, acquisitions of businesses and intellectual property rights, payments relating to purchases of surgical instruments, repayments of borrowings under the Amended Credit Facility, and payments due under the Orthotec settlement agreement. We expect that our principal uses of cash in the future will be for operations, working capital, capital expenditures, and potential acquisitions. We expect that, as our revenues grow, our sales and marketing and research and development expenses will continue to grow and, as a result, we will need to generate significant net revenues to achieve profitability. We anticipate that we will raise additional capital through borrowings under our Amended Credit Facility, the incurrence of other indebtedness, additional equity financings or a combination of these potential sources of liquidity.

We will need to invest in working capital and surgical instruments in order to support our revenue projections through the end of 2016. If we are not able to achieve our revenue forecast and cash consumption starts to exceed forecasted consumption, management will need to adjust our investment in surgical instruments and manage our inventory to the decreased sales volumes. If we do not make these adjustments in a timely manner, there could be an adverse impact on our financial resources. Our revenue projections may be negatively impacted as a result of a decline in sales of our products, including declines due to changes in our customers’ ability to obtain third-party coverage and reimbursement for procedures that use our products, increased pricing pressures resulting from intensifying competition, and cost increases and slower product development cycles resulting from a changing regulatory environment.

On July 6, 2015, we announced a restructuring of our manufacturing operations in California in an effort to improve our cost structure. The restructuring includes a reduction in workforce and closing the California manufacturing facility. As of June 30, 2016, this restructuring is substantially complete.

A substantial portion of our available cash funds is held in business accounts with reputable financial institutions. At times, however, our deposits, may exceed federally insured limits and thus we may face losses in the event of insolvency of any of the financial institutions where our funds are deposited. We did not hold any marketable securities as of June 30, 2016.

Amended Credit Facility and Other Debt

On August 30, 2013, we entered into the Amended Credit Facility with MidCap. The Amended Credit Facility amended and restated the prior credit facility that we had with MidCap (the "Prior Credit Facility"). Pursuant to the Amended Credit Facility, we increased the borrowing limit from $50 million to $73 million. We also extended the maturity to August 2016. In July 2015, we further amended the Amended Credit Facility to provide for an additional term loan of $5 million. As of June 30, 2016, the Amended Credit Facility consisted of a $38 million term loan, $25 million of which was outstanding as of June 30, 2016 and a revolving line of credit with a maximum borrowing base of $40 million, of which $28 million was outstanding under the revolving line of credit at June 30, 2016. We used the term loan proceeds of $28 million drawn at closing to repay a portion of the outstanding balance on the prior revolving line of credit.

The term loan interest rate is priced at the London Interbank Offered Rate, or LIBOR, plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate remains priced at LIBOR plus 6.0%, reset monthly. At June 30, 2016, the revolving line of credit carried an interest rate of 6.5% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, we granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in our subsidiaries. In addition to monthly payments of interest, monthly repayments of $0.5 million are due through maturity, with the remaining principal due upon maturity.

The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by us. The Amended Credit Facility also includes several event of default provisions, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.

On March 17, 2014, we entered into the First Amendment to the Amended Credit Facility with MidCap, or the First Amendment to the Amended Credit Facility. Under the First Amendment to the Amended Credit Facility, MidCap gave us its consent to enter into the Facility Agreement and make settlement payments in connection with the Orthotec litigation. The First Amendment to the Amended Credit Facility also added a total leverage ratio financial covenant.

On July 10, 2015, we entered into a Second Amendment to the Amended Credit Facility with MidCap, or the Second Amendment, to increase the term loan commitment from $33 million to $38 million. We borrowed the additional $5 million on July 10, 2015, which is the third term loan tranche under the Amended Credit Facility, or the Third Term Loan Tranche. Until January 1, 2016, only interest payments were due for the Third Term Loan Tranche. Thereafter, we are required to pay an amount equal to $0.5 million on the first day of each calendar month as an amortization payment in respect of all tranches of the term loan. We agreed to pay MidCap, a commitment fee equal to 1.0% of the principal amount of the funds disbursed in the Third Term Loan Tranche.

On March 11, 2016, we entered into a third amendment and waiver to the Amended Credit Facility with MidCap, or the Third Amendment to the Amended Credit Facility. The Third Amendment to the Amended Credit Facility extends the maturity date of the Amended Credit Facility from August 30, 2016 to December 31, 2016 and contains an amendment fee in the amount of $0.5 million, which is due and payable at the earlier of the termination of the Amended Credit Facility or the maturity date. The Third Amendment to the Amended Credit Facility also contains a waiver of the December 2015 defaults under the Facility Agreement, provides a waiver for the fixed charge coverage ratio for January 2016 and eliminates the fixed charge coverage ratio covenant for February 2016. At June 30, 2016, $0.7 million remains as unamortized debt discount related to the Amended Credit Facility and the prior credit facility with MidCap within the unaudited consolidated balance sheet, which will be amortized over the remaining term of the Amended Credit Facility.

On August 8, 2016, we entered into a fourth amendment to the Amended Credit Facility with MidCap, or the Fourth Amendment to the Amended Credit Facility. The Fourth Amendment to the Amended Credit Facility provides for a $2.2 million increase to the borrowing base until September 15, 2016, and includes an amendment fee of $0.2 million, which was due and payable on August 8, 2016. The Fourth Amendment to the Amended Credit Facility also contains a waiver for the May and June 2016 non-compliances.

The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by us. The Amended Credit Facility also provides for several event of default provisions, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.

We were not in compliance with certain of the financial covenants of the Amended Credit Facility during the three months ended June 30, 2016, as discussed above. We have obtained waivers from MidCap and Deerfield with respect to the non-compliance during such periods. There is no assurance that we will be in compliance with the financial covenants of the Amended Credit Facility for July 2016 or in the future.

On March 17, 2014, we entered into the Facility Agreement, pursuant to which Deerfield agreed to loan us up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, we had the option, but were not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015, provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described above, or the Litigation Satisfaction. Following such initial draw down, we had the opportunity to draw down additional amounts under the Facility Agreement up to an aggregate of $15.0 million for working capital or general corporate purposes. We agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed in addition to the issuance of additional warrants to purchase up to 10,000,000 shares of our common stock to Deerfield. On March 20, 2014, we drew $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the Orthotec settlement payment obligations due in 2014. On November 21, 2014, we drew an additional $6 million under the Facility Agreement and received net proceeds of $5.9 million to fund Orthotec settlement payment obligations through 2016. The unused proceeds from the Facility Agreement are classified as restricted cash and may not be used for other purposes. As of January 30, 2015, we can no longer draw down additional funds under the Facility Agreement. Amounts borrowed under the Facility Agreement are payable in March 2017, March 2018 and March 2019, which are the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due on March 20, 2019.

In connection with the execution of the Facility Agreement, we issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of our common stock, or the Initial Warrants. Additionally, we agreed that upon each disbursement under the Facility Agreement we would issue to Deerfield warrants to purchase up to 10,000,000 shares of our common stock, in proportion to the amount of draw compared to the total $50 million facility, or the Draw Warrants.

On March 20, 2014, we made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that were due in 2014. The $0.5 million transaction fee was recorded as a debt discount and is being amortized over the term of the draw, which ends on March 20, 2019. In connection with this borrowing, we issued Draw Warrants to purchase 4,000,000 shares of common stock, which were valued at $4.7 million and recorded as a debt discount and are being amortized over the term of the draw. Additionally, $2.3 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method.

On November 21, 2014, we made a second draw of $6.0 million under the Facility Agreement and received net proceeds of $5.9 million to fund the portion of the Orthotec settlement payments through July 2016. The $0.2 million transaction fee was recorded as a debt discount and is being amortized over the remaining term of the draw, which ends on March 20, 2019. In connection with this borrowing, we issued Draw Warrants to purchase 1,200,000 shares of common stock, which were valued at $0.9 million and recorded as a debt discount and is being amortized over the term of the debt using the effective interest method.

On July 10, 2015, we entered into a First Amendment to the Facility Agreement, or the Facility Agreement First Amendment, with Deerfield. The Facility Agreement First Amendment permitted us, among other things, to enter into and borrow the additional $5.0 million under the term loan in July 2015 under the Second Amendment to the Amended Credit Facility.

On February 5, 2016, we entered into a Limited Waiver and Second Amendment to the Facility Agreement, or the Facility Agreement Second Amendment. The Facility Agreement Second Amendment increases the interest rate under the Facility Agreement from 8.75% per annum to 14.75% per annum. In addition, under the Facility Agreement Second Amendment we may elect to have (i) until August 30, 2016, six percent (6%), and (ii) thereafter, three percent (3%), in each case, of the interest on the outstanding principal amount under the Facility Agreement paid in kind, which would be added to the outstanding principal amount under the Facility Agreement and bear interest at the interest rate of 14.75% per annum, hereinafter referred to as the PIK Interest. All accrued and unpaid PIK Interest is due and payable when the outstanding amounts under the Facility Agreement are due and payable thereunder or are fully repaid, whichever occurs first. The Facility Agreement Second Amendment also contains an amendment fee in the amount of $0.6 million, which is due and payable in installments of $0.2 million in March 2017, March 2018 and March 2019 on the third, fourth and fifth anniversaries of the Facility Agreement; provided, that all unpaid amendment fees shall be due and payable when the outstanding amounts under the Facility Agreement are due and payable or are fully repaid, whichever occurs first. The Facility Agreement Second Amendment also changes the prior date of March 31, 2017 to March 31, 2018, as the date through which we must pay interest in the event we prepay amounts outstanding under the Facility Agreement prior to such date. The Facility Agreement Second Amendment also contains the waivers of the defaults under the Facility Agreement for the fixed charge coverage ratio through March 2016, but not for the default under the senior leverage ratio or total leverage ratio financial covenants.

Due to our non-compliance with certain of the financial covenants of the Amended Credit Facility, we were in cross-default of the Facility Agreement during the six months ended June 30, 2016, as discussed above. We have obtained waivers from Deerfield with respect to the cross-defaults during these periods. There is no assurance that we will not be in default of the Facility Agreement for July 2016 or in the future.

As of June 30, 2016, Orthotec settlement payments of $25.2 million have been made, leaving remaining proceeds from the funds borrowed under the Facility Agreement of $0.2 million, which are classified as short-term restricted cash, as their use is limited under the terms of the Facility Agreement for the payments of amounts due under the Orthotec litigation settlement agreement. Additionally, an Orthotec settlement payment of $1.1 million was made on July 1, 2016, of which $1.0 million was paid by proceeds from a forbearance agreement with HealthpointCapital, which we are required to repay to HealthpointCapital no later than September 30, 2016. As of August 8, 2016, there remains aggregate of $31.5 million of Orthotec settlement payments to be paid by us. The amounts borrowed under the Facility Agreement, which total $26.6 million in principal, accrued amendment fee and accrued interest as of June 30, 2016, are due in three equal annual payments beginning March 20, 2017. Additionally, $0.2 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method.

Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property, which is subordinated to the security interest granted under the Amended Credit Facility.

We have various capital lease arrangements. The leases bear interest at rates ranging from 6.6% to 9.6%, are generally due in monthly principal and interest installments, are collateralized by the related equipment, and have various maturity dates through September 2018. As of June 30, 2016, the balance of these capital leases, net of interest totaled $1.1 million.

NASDAQ Notice for Failure to Satisfy Continued Listing Rules

Our common stock is currently listed on the NASDAQ Global Select Market. In order to maintain that listing, we must satisfy minimum financial and other requirements. On September 17, 2015, we received written notice from the Listing Qualifications Department of the NASDAQ Stock Market LLC, or NASDAQ, notifying us that for the preceding 30 consecutive business days, our common stock did not maintain a minimum closing bid price of $1.00 per share as required for continued inclusion on The NASDAQ Global Select Market under NASDAQ Listing Rule 5450(a)(1). The notification letter stated that pursuant to NASDAQ Listing Rule 5810(c)(3)(A), we would be afforded 180 calendar days, or until March 15, 2016, to regain compliance with the minimum bid price requirement. On March 21, 2016, we were notified by NASDAQ that we had not regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Marketplace Rule 5450(a)(1) and that our common stock would be subject to delisting unless we timely request a hearing before the NASDAQ Listing Qualifications Panel, or the Panel. On April 21, 2016 we had a hearing with NASDAQ, at which we requested an extension within which to pursue our plan to regain and maintain compliance with all applicable requirements for continued listing on NASDAQ. On May 2, 2016 we were informed that NASDAQ had approved our compliance plan and agreed to allow the continued listing of our common stock on NASDAQ until September 12, 2016, at which time we must be in compliance. While our common stock will remain listed and continue to trade on NASDAQ under the symbol “ATEC”, there can be no assurance that we will be able to regain compliance prior to September 12, 2016.

A delisting of our common stock from The NASDAQ Global Select Market and our failure to transfer our listing to The NASDAQ Capital Market could substantially further reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

Operating Activities

We generated net cash of $10.1 million from operating activities for the six months ended June 30, 2016. During this period, net cash provided by operating activities primarily consisted of a net loss of $11.9 million and working capital and other assets used cash of $8.0 million, which were offset by $13.9 million of non-cash costs including amortization, depreciation, deferred income taxes, stock-based compensation, provision for doubtful accounts, provision for excess and obsolete inventory, and interest expense related to amortization of debt discount and issue costs. Working capital and other assets used of $8.0 million primarily consisted of decreases in accounts receivable of $2.9 million, restricted cash of $2.2 million, prepaid expenses and other current assets of $1.3 million and increases in accounts payable of $3.1 million, and deferred revenue of $0.1 million, partially offset by an increase in inventories of $0.1 million and a decrease in accrued expenses of $1.8 million.

Investing Activities

We used cash of $4.4 million, net of accounts payable, in investing activities for the six months ended June 30, 2016, with the majority of $5.7 million being used for the purchase of surgical instruments.

Financing Activities

Financing activities used net cash of $5.8 million for the six months ended June 30, 2016. On the Amended Credit Facility with MidCap we borrowed an aggregate of $70.2 million and made principal payments totaling $71.0 million during the six months ended June 30, 2016. We made principal payments on notes payable and capital leases totaling $5.0 million in the six months ended June 30, 2016.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual obligations and commercial commitments

Total contractual obligations and commercial commitments as of June 30, 2016 are summarized in the following table (in thousands):



	Payment Due by Year
			2016
	Total		(6 months)		2017		2018		2019		2020		Thereafter
Amended Credit Facility with MidCap ⁽¹⁾	52,991		$	52,991	$	—	$	—	$	—	$	—	$	—
Facility Agreement with Deerfield ⁽¹⁾	26,636		—		8,867		8,867		8,902		—		—
Interest expense ⁽¹⁾	9,234		3,997		2,331		1,302		1,604		—		—
Notes payable for software licenses	223		223		—		—		—		—		—
Note payable for insurance premiums	147		147		—		—		—		—		—
Capital lease obligations	934		429		437		68		—		—		—
Operating lease obligations	9,573		1,817		2,152		1,688		1,520		1,494		902
Litigation settlement obligations	32,633		2,200		4,400		4,400		4,400		4,400		12,833
Guaranteed minimum royalty obligations	4,776		972		1,450		1,368		618		368		—
Stock price guarantee ⁽²⁾	4,248		—		2,119		2,129
New product development milestones ⁽³⁾	400		—		200		—		200		—		—
Total	$	141,795	$	62,776	$	21,956	$	19,822	$	17,244	$	6,262	$	13,735

__________________________

(1)

The amounts above are presented based on the contractual payment schedule in each of the respective agreements. However, the debt balance under the Amended Credit Facility and Facility Agreement was callable as of June 30, 2016 due to the events of default (See Note 1 of the notes to condensed consolidated financial statements) and therefore, is presented as a current liability in the condensed consolidated balance sheet as of June 30, 2016.


(2)	Based on our closing stock price as of June 30, 2016 of $0.35 per share. The actual cash obligation will vary depending on the price of our common stock on the settlement dates.


(3)	This commitment represents payments in cash, and is subject to attaining certain sales milestones, development milestones such as U.S. Food and Drug Administration approval, product design and functionality testing requirements, which we believe are reasonably likely to be achieved during the period from 2016 through 2019.

Stock-based Compensation

Stock-based compensation has been classified as follows in the accompanying condensed consolidated statements of operations (in thousands, except per share data):



	Three Months Ended June 30,					Six Months Ended June 30,
	2016		2015			2016		2015
Cost of revenues	$	8	$	31		$	14	$	53
Research and development	31		469			24		1,027
Sales and marketing	45		128			47		253
General and administrative	222		637			278		1,185
Total	$	306	$	1,265		$	363	$	2,518
Effect on basic and diluted net loss per share	$	—	$	(0.01	)	$	—	$	(0.03	)

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB, issued new accounting guidance related to revenue recognition. This new standard replaces all current U.S. GAAP guidance on this topic and eliminates all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers

in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance, including all subsequent clarifications, is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of adopting this new accounting standard on our financial statements.

In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods thereafter. We are currently evaluating the impact of this guidance and expect to adopt the standard for the annual reporting period ending December 31, 2016.

In April 2015, the FASB issued guidance, which amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Prior to the issuance this guidance, debt issuance costs were required to be presented as an asset in the balance sheet. We adopted the provisions of the new guidance during the interim period ended March 31, 2016 and prior period amounts have been reclassified to conform to the current period presentation. As of December 31, 2015, $0.4 million of debt issuance costs were reclassified in the consolidated balance sheet from prepaid expenses and other current assets to current portion of long-term debt. The adoption of this guidance did not impact our consolidated statement of operations, comprehensive loss or cash flows.

In July 2015, the FASB issued new accounting guidance, which changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value for entities that do not measure inventory using the last-in, first-out or retail inventory method. The guidance also eliminates the requirement for these entities to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently evaluating the impact of adopting this new accounting standard on our financial statements.

In February 2016, the FASB issued new accounting guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months to be recognized on the balance sheet. The guidance is effective for annual periods and interim periods in fiscal years beginning after December 15, 2018. We are currently evaluating the impact of adopting this new accounting standard on our financial statements.

In March 2016, the FASB issued new accounting guidance, which changes several aspects of the accounting for share-based payment award transactions, including accounting and cash flow classification for excess tax benefits and deficiencies, forfeitures, and tax withholding requirements and cash flow classification. The guidance is effective for annual periods and interim periods in fiscal years beginning after December 15, 2016. We are currently evaluating the impact of adopting this new accounting standard on our financial statements.

Forward Looking Statements

This Quarterly Report on Form 10-Q incorporates a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act, including statements regarding:


•	our estimates regarding anticipated operating losses, future revenue, expenses, cost savings, capital requirements, uses and sources of cash and liquidity;


•	our ability to meet the financial covenants under our credit facilities, to obtain waivers from our lenders with respect to any noncompliance with our financial covenants, and to refinance our existing debt prior to the maturity of our credit facilities with our current or new lenders;


•	our ability to regain and maintain compliance with the continued listing requirements of The NASDAQ Global Select Market;


•	our ability to ensure that we have effective disclosure controls and procedures and to remedy our material weaknesses in our internal control over financial reporting;

•

our proposed transaction with Globus Medical, including our and Globus’s ability to satisfy the conditions to closing on the anticipated timeline or at all, our ability to execute on our business plan and conduct our business in the ordinary course through the closing; disruption of our business and diversion of our management’s time and attention in order to transition the international business and close the transaction; our ability to reduce our operating expenses by $20 million over the next two years; our not realizing the full economic benefit from the transaction, including as a result of indemnification claims under the definitive agreement and the retention by us of certain liabilities associated with the international business, and our ability to meet our obligations under the supply agreement;


•	our ability to meet and potential liability from not meeting the payment obligations under the Orthotec settlement agreement;


•	our ability to regain and maintain compliance with the quality requirements of the FDA and similar regulatory authorities outside of the U.S., including our ability to resolve the deficiencies cited in the Warning Letter that we received from the FDA in July 2015 following the FDA's inspection of our manufacturing facilities;


•	our ability to market, improve, grow, commercialize and achieve market acceptance of any of our products or any product candidates that we are developing or may develop in the future;


•	our beliefs about the features, strengths and benefits of our products;


•	our ability to continue to enhance our product offerings, outsource our manufacturing operations and expand the commercialization of our products, and the effect of our strategy;


•	our expectations about the timing, costs and benefits of the restructuring and outsourcing of our manufacturing operations;


•	our beliefs about the ability of our supplier relationships and quality processes to fulfill our production requirements;


•	our ability to successfully integrate, and realize benefits from licenses and acquisitions;


•	our ability to successfully achieve and maintain regulatory clearance or approval for our products in applicable jurisdictions and in a timely manner;


•	the effect of any existing or future federal, state or international regulations on our ability to effectively conduct our business;


•	our estimates of market sizes and anticipated uses of our products;


•	our business strategy and our underlying assumptions about market data, demographic trends, reimbursement trends and pricing trends;


•	our ability to achieve profitability, and the potential need to raise additional funding;


•	our ability to maintain an adequate sales network for our products, including to attract and retain independent distributors;


•	our ability to enhance our U.S. and international sales and distributions networks and product penetration;


•	our ability to increase the use and promotion of our products by training and educating surgeons and our sales network;


•	our ability to attract and retain a qualified management team, as well as other qualified personnel and advisors;


•	our ability to enter into licensing and business combination agreements with third parties and to successfully integrate the acquired technology and/or businesses;


•	our management team’s ability to accommodate growth and manage a larger organization;


•	our ability to protect our intellectual property, and to not infringe upon the intellectual property of third parties;


•	the effects of the escalating cost of medical products and services and the effects of market demand, government regulation, third-party reimbursement policies and societal pressures on the worldwide healthcare industry and our business;


•	our ability to meet or exceed the industry standard in clinical and legal compliance and corporate governance programs;


•	our beliefs about our competitors and the principal competitive factors in our market and the effect of non-operative treatments on demand for our products;


•	potential liability resulting from litigation;


•	our beliefs about our employee relations;


•	potential liability resulting from a governmental review of our business practices;


•	our beliefs about the usefulness of the non-GAAP financial measures included in this Quarterly Report on Form 10-Q;


•	our beliefs with respect to our critical accounting policies and the reasonableness of our estimates and assumptions; and


•	other factors discussed elsewhere in this Quarterly Report on Form 10-Q or any document incorporated by reference herein or therein.

Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions and/or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results.

We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC. These are factors that we think could cause our actual results to differ materially from expected results. Other factors besides those listed there could also adversely affect us.

Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “estimate,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “continue,” “project,” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control, including the factors set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015 and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.



Item 3.	Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Our borrowings under our credit facilities expose us to market risk related to changes in interest rates. As of June 30, 2016, our outstanding floating rate indebtedness totaled $53.0 million. The primary base interest rate is the LIBOR rate. Assuming the outstanding balance on our floating rate indebtedness remains constant over a year, a 100 basis point increase in the interest rate would decrease pre-tax income and cash flow by approximately $0.6 million. Other outstanding debt consists of fixed rate instruments, including debt outstanding under the Facility Agreement, notes payable and capital leases.

Foreign Currency Risk

Our exposure to foreign currency transaction gains and losses is primarily the result of certain net receivables due from our foreign subsidiaries and customers being denominated in currencies other than the U.S. Dollar, primarily the Euro and Japanese Yen, in which our revenues and profits are denominated. We had unfavorable foreign currency exchange results realized in 2015 due to having U.S. Dollar denominated assets and liabilities on foreign subsidiaries books. We do not currently engage in hedging or similar transactions to reduce these risks. Fluctuations in currency exchange rates could impact our results of operations, financial position and cash flows.

Commodity Price Risk

We purchase raw materials that are processed from commodities, such as titanium and stainless steel. These purchases expose us to fluctuations in commodity prices. Given the historical volatility of certain commodity prices, this exposure can impact our product costs. However, because our raw material prices comprise a small portion of our cost of revenues, we have not experienced any material impact on our results of operations from changes in commodity prices. A 10% change in commodity prices would not have had a material impact on our results of operations for the six months ended June 30, 2016.

Equity Price Risk

In connection with the Facility Agreement with Deerfield, we have issued warrants to purchase 11,450,000 shares of our common stock. We recorded the warrant liability at fair value and adjust the carrying value of these common stock warrants to their estimated fair value at each reporting date, with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in our consolidated statement of operations. A 10% increase in our stock price from its June 30, 2016 closing price of $0.35 per share would increase the fair value of the warrant liability by approximately $0.1 million with a corresponding charge to the Statements of Operations.



Item 4.	Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s, or SEC's, rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective, as a result of the material weakness below, to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

In our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 15, 2016, we reported a material weakness in our internal control over financial reporting in which we failed to design effective controls over the release of inventory cost through cost of goods sold at our significant wholly owned subsidiary. To address the material weakness described above, during the first quarter of 2016, we designed and implemented new and enhanced compensating controls at the consolidated level to ensure that the calculation of inventory cost release is accurate and that the appropriate level of review is performed. We are in the process of developing and implementing additional processes and controls at the wholly owned subsidiary. We are also in the process of providing additional training to personnel involved in the costing of inventory at our wholly owned subsidiary. We believe that these remediation measures have strengthened our internal control over financial reporting and are remediating the material weakness we had identified. We will continue to monitor the effectiveness of these controls and will make any further changes management determines appropriate.

Except for the remediation measures disclosed above, there were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the quarter ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION



Item 1.	Legal Proceedings

Litigation

We are and may become involved in various legal proceedings arising from our business activities. While we are not aware of any litigation matter that in and of itself would have a material adverse impact on our consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of a proceeding, an unfavorable resolution could materially affect our future consolidated results of operations, cash flows or financial position in a particular period. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual or disclosure in our consolidated financial statements. An estimated loss contingency is accrued in our consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, we may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against us may be unsupported, exaggerated or unrelated to reasonably possible outcomes, and as such are not meaningful indicators of our potential liability.



Item 1A.	Risk Factors

There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on March 15, 2016, except as follows:

We may be unable to comply with the covenants of our credit facilities.

We must comply with certain affirmative and negative covenants, including financial covenants, in our credit facility with MidCap and affirmative and negative covenants in our Facility Agreement with Deerfield. We failed to comply with the fixed charge coverage ratio for January and June 2016, the fixed charge coverage ratio, senior leverage ratio and total leverage ratio covenants for March 2016, and the fixed charge coverage ratio and total leverage ratio covenants for April and May 2016, under our credit facility with MidCap. We also did not meet a minimum requirement for the percentage of our total cash held in U.S. accounts for January, February, March, April, May and June 2016. MidCap and Deerfield have provided waivers with respect to our non-compliance during such periods. In March 2016, we received waivers from MidCap and Deerfield for the January non-compliance. In May 2016, MidCap and Deerfield provided waivers for the February and March non-compliances, in June 2016, MidCap and Deerfield provided waivers for the April non-compliances and in August, MidCap and Deerfield provided waivers for the May and June non-compliances. There can be no assurance that at all times in the future we will satisfy all such financial or other covenants of the MidCap credit facility or the Deerfield Facility Agreement, or obtain any required waiver or amendment, in which event of default the lenders party to the MidCap credit facility could refuse to make further extensions of credit to us and MidCap and/or Deerfield could require all amounts borrowed under the MidCap credit facility and/or the Facility Agreement, respectively, together with accrued interest and other fees, to be immediately due and payable. In addition to allowing the lenders to accelerate the loan, several events of default under the MidCap credit facility, such as our failure to make required payments of principal and interest and the occurrence of certain bankruptcy or insolvency events, could require us to pay interest at a rate which is up to five percentage points higher than the interest rate effective immediately before the event of default.

An event of default under the MidCap credit facility or the Deerfield Facility Agreement could have a material adverse effect on us. Upon an event of default, if the lenders under the MidCap credit facility accelerate the repayment of all amounts borrowed, together with accrued interest and other fees, or if the lenders elect to charge us additional interest, we cannot assure you that we will have sufficient cash available to repay the amounts due, and we may be forced to seek to amend the terms of the MidCap credit facility or the Deerfield Facility Agreement or obtain alternative financing, which may not be available to us on acceptable terms, if at all.

In addition, if we fail to pay amounts when due under the MidCap credit facility or the Deerfield Facility Agreement or upon the occurrence of another event of default, the lenders under the MidCap credit facility or the Deerfield Facility Agreement could proceed against the collateral granted to them pursuant to the MidCap credit facility and the Deerfield

Facility Agreement. We have granted to the lenders under the MidCap credit facility a first priority security interest in substantially all of our assets, including all accounts receivable and all securities evidencing our interests in our subsidiaries, as collateral under the MidCap credit facility. If the lenders proceed against the collateral, such assets would no longer be available for use in our business, which would have a significant adverse effect our business, financial condition and results of operations.

If we fail to continue to meet all applicable NASDAQ Global Select Market requirements and our common stock is delisted, the delisting could adversely affect the market liquidity of our common stock, impair the value of your investment and harm our business.

If we fail to continue to meet all applicable NASDAQ Global Select Market requirements in the future and NASDAQ determines to delist our common stock, the delisting could substantially decrease trading in our common stock and adversely affect the market liquidity of our common stock; adversely affect our ability to obtain financing on acceptable terms, if at all, to continue our operations; and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. Additionally, the market price of our common stock may decline further and stockholders may lose some or all of their investment. The closing bid price of our common stock on the NASDAQ Global Select Market was $0.40 per share on August 8, 2016.

If we are unable to close the pending sale of our international business, it may adversely affect our business and operations and impact our ability to continue as a going concern.

On July 25, 2016, we entered into a purchase and sale agreement, or the Purchase and Sale Agreement, with Globus Medical Ireland, Ltd., or the Buyer, a subsidiary of Globus Medical, Inc., or Globus, pursuant to which, and on the terms and subject to the conditions thereof, among other things, the Buyer agreed to acquire substantially all of our international distribution operations and agreements, including our wholly-owned subsidiaries in Japan and Brazil and the assets of our other sales operations in the United Kingdom and Italy.

The closing of the transaction, or the Closing, is subject to the satisfaction or waiver of a number of conditions set forth in the Purchase and Sale Agreement, including, among other things, (i) the accuracy of the representations and warranties and compliance with covenants contained in the Purchase and Sale Agreement, (ii) the absence of a material adverse effect in our international business that we are selling pursuant to Purchase and Sale Agreement, (iii) the absence of any law or order by any governmental authority that would make illegal or otherwise prohibit the consummation of the transactions under the Purchase and Sale Agreement, (iv) all required consents of, notifications to and filings with any governmental authority shall have been made and any waiting periods shall have expired, (v) the receipt of specified third-party consents, (vi) the Company and Globus entering into the Globus Facility Agreement, (vii) the Company and Buyer entering into a product manufacture and supply agreement, (viii) the Company and Buyer entering into a transition services agreement, (ix) the Buyer and MidCap entering into an intercreditor agreement, and (x) the extension of the term of a specified distribution agreement with one of our international distributors.

We expect the Closing to occur by October 2016, subject to the satisfaction of the foregoing closing conditions. Either party may terminate the Purchase and Sale Agreement if the Closing has not occurred by October 1, 2016 (subject to an extension until October 15, 2016 to allow the Buyer to put systems in place to allow it to process orders of our products through its IT and customer service systems as of the Closing). We and the Buyer may also terminate the Purchase and Sale Agreement by mutual consent, for a material breach by the other party or if a final governmental order prohibiting the transaction is issued.

If the Closing does not occur, we will not have access to the $30 million credit facility from Globus, which would have a material impact on our liquidity. In addition, if the Closing does not occur, we will be unable to use a portion of the proceeds from the transaction to repay in full all amounts outstanding and due under the Deerfield Facility Agreement and repay certain of our outstanding indebtedness under the MidCap Amended Credit Facility, which would increase the likelihood that our noncompliance with the covenants under these credit facilities would continue and may adversely affect our ability to repay our indebtedness, our financial condition and our ability to continue as a going concern.

In addition, if the Closing does not occur, our management and other employees will have expended extensive time and effort and their focus and attention will have been diverted from operational matters during the pendency of the transaction, and will have incurred significant third party transaction costs, in each case, without any commensurate benefit, which may have a material and adverse effect on our financial condition and results of operations.

We may face indemnity and other liability claims pursuant to the Purchase and Sale Agreement.

Under the Purchase and Sale Agreement, we will indemnify the Buyer against damages arising from, among other things, breaches of our representations, warranties or obligations under the Purchase and Sale Agreement and liabilities not assumed by the Buyer. The indemnification period generally runs for a period of 18 months from the Closing, with longer survival periods for certain specified representations and warranties. Our indemnification obligations are subject to a deductible in certain cases of $500,000, and our aggregate liability under such indemnification claims is generally limited to $12.0 million, $20.0 million for certain specified representations and warranties, and the full purchase price for breaches of certain specified representations and warranties, breaches of covenants and certain other matters. If the Buyer makes an indemnification claim, we may incur liability and/or expenses, which could harm our operating results. In addition, such indemnity claims may divert management attention from our continuing business.

The sale of our international distribution operations and agreements will reduce our revenue.

During the six months ended June 30, 2016, our International revenue represented approximately 35.3% of our total revenue. Following the Closing, our revenues will be reduced as we will no longer be generating the same level of revenue from the operations and assets sold in the transaction. There can be no assurance that the proceeds from the Globus transaction will be sufficient for us to grow our U.S. business.

Our stockholders will not receive any distribution of the proceeds from the sale of our international distribution operations, and may never receive any return of value.

We do not intend to distribute to stockholders any cash proceeds from the Globus transaction. Instead, we intend to use the proceeds from the transaction to repay in full all amounts outstanding and due under our Facility Agreement with Deerfield and repay certain of our outstanding indebtedness under our Amended Credit Facility with MidCap, to fund our future business activities and for general working capital purposes. Any future decision for the use of those funds will be made by our board of directors.

In addition, we have not declared any cash dividends and do not intend to declare or pay any cash dividends in the foreseeable future. Future earnings, if any, will be used to finance the future operation and growth of our business. Stockholders will not receive any liquidity from the transaction and the only return to them will be based on any future appreciation in our stock price or upon a future sale or liquidation of our company. Much depends on our future business, including the success or failure of our U.S. business. There are no assurances that we will be successful, and current stockholders may never get a return on their investment.



Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None

Issuer Purchases of Equity Securities

Under the terms of our Amended and Restated 2005 Employee, Director and Consultant Stock Plan, as amended, or the Stock Plan, and prior to the expiration of the Stock Plan in April 2016, we were permitted to award shares of restricted stock to our employees, directors and consultants. These shares of restricted stock are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase in the event that a restricted stock recipient’s employment, directorship or consulting relationship with us terminates prior to the end of the vesting period. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares. Repurchased shares are returned to the Stock Plan and are available for future awards under the terms of the Stock Plan.

Period

Total Number

of Shares

Purchased

Average Price

Paid per

Total Number of

Shares Purchased

as part of Publicly

Announced Plans

or Programs

Maximum Number

of Shares That May

Yet Be Purchased

Under the Plans or

Programs

April 1, 2016 through April 30, 2016

—

May 1, 2016 through May 31, 2016

—

June 1, 2016 through June 30, 2016

—

(1)

Not included in the table above are 2,737 shares of common stock forfeited and retired in connection with the payment of minimum statutory withholding taxes due upon the vesting of certain stock awards or the exercise of certain stock options. In lieu of making a cash payment with respect to such withholding taxes, the holders of such stock forfeited a number of shares at the then current fair market value of the shares to pay such taxes.



Item 3.	Defaults Upon Senior Securities

The Company has determined that it failed to comply with the fixed charge coverage ratio for January and June 2016, the fixed charge coverage ratio, senior leverage ratio and total leverage ratio covenants for March 2016, and the fixed charge coverage ratio and total leverage ratio covenants for April and May 2016, under its Amended Credit Facility with MidCap. The Company also did not meet a requirement for the percentage of the Company's total cash held in U.S. accounts for January, February, March, April, May and June 2016. The Company’s default under the MidCap credit facility also constitutes an event of default under the Facility Agreement with Deerfield. In March 2016, the Company received waivers from MidCap and Deerfield for January non-compliance with the Amended Credit Facility Agreement and Facility Agreement, respectively. In May 2016, MidCap and Deerfield provided waivers for the February and March non-compliances with the Amended Credit Facility Agreement and the Facility Agreement, respectively. In June 2016, MidCap and Deerfield provided waivers for the April non-compliance with the Amended Credit Facility Agreement and Facility Agreement, respectively. In August 2016, MidCap and Deerfield provided waivers for the May and June 2016 non-compliances with the Amended Credit Facility Agreement and the Facility Agreement, respectively. The Company can provide no assurance that it will be in compliance with the financial covenants for July 2016 or in the future. If the Company does not obtain waivers from MidCap or Deerfield for any existing or future non-compliance with the Amended Credit Facility and/or Facility Agreement, MidCap and Deerfield would each have the right to call their respective debts due immediately, which would significantly impact the Company's ability to continue as a going concern.



Item 6.	Exhibits



Exhibit Number	Exhibit Description

31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101	The following materials from the Alphatec Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (Unaudited) as of June 30, 2016 and December 31, 2015, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2016 and 2015, (iii) Condensed Consolidated Statements of Comprehensive Loss (Unaudited) for the three and six months ended June 30, 2016 and 2015, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2016 and 2015, and (v) Notes to Condensed Consolidated Financial Statements (Unaudited).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



ALPHATEC HOLDINGS, INC.

By:	/s/ James M. Corbett
	James M. Corbett President and Chief Executive Officer (principal executive officer)

By:	/s/ Michael O’Neill
	Michael O’Neill Chief Financial Officer, Vice President and Treasurer (principal financial officer and principal accounting officer)

Date: August 9, 2016

Exhibit Index



Exhibit Number	Exhibit Description

31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101	The following materials from the Alphatec Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (Unaudited) as of June 30, 2016 and December 31, 2015, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2016 and 2015, (iii) Condensed Consolidated Statements of Comprehensive Loss (Unaudited) for the three and six months ended June 30, 2016 and 2015, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2016 and 2015, and (v) Notes to Condensed Consolidated Financial Statements (Unaudited).